CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer's disease
- PMID: 35764973
- PMCID: PMC9241248
- DOI: 10.1186/s13024-022-00545-9
CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer's disease
Abstract
Background: Despite its identification as a key checkpoint regulator of microglial activation in Alzheimer's disease, the overarching role of CX3CR1 signaling in modulating mechanisms of Aβ driven neurodegeneration, including accumulation of hyperphosphorylated tau is not well understood.
Methodology: Accumulation of soluble and insoluble Aβ species, microglial activation, synaptic dysregulation, and neurodegeneration is investigated in 4- and 6-month old 5xFAD;Cx3cr1+/+ and 5xFAD;Cx3cr1-/- mice using immunohistochemistry, western blotting, transcriptomic and quantitative real time PCR analyses of purified microglia. Flow cytometry based, in-vivo Aβ uptake assays are used for characterization of the effects of CX3CR1-signaling on microglial phagocytosis and lysosomal acidification as indicators of clearance of methoxy-X-04+ fibrillar Aβ. Lastly, we use Y-maze testing to analyze the effects of Cx3cr1 deficiency on working memory.
Results: Disease progression in 5xFAD;Cx3cr1-/- mice is characterized by increased deposition of filamentous plaques that display defective microglial plaque engagement. Microglial Aβ phagocytosis and lysosomal acidification in 5xFAD;Cx3cr1-/- mice is impaired in-vivo. Interestingly, Cx3cr1 deficiency results in heighted accumulation of neurotoxic, oligomeric Aβ, along with severe neuritic dystrophy, preferential loss of post-synaptic densities, exacerbated tau pathology, neuronal loss and cognitive impairment. Transcriptomic analyses using cortical RNA, coupled with qRT-PCR using purified microglia from 6 month-old mice indicate dysregulated TGFβ-signaling and heightened ROS metabolism in 5xFAD;Cx3cr1-/- mice. Lastly, microglia in 6 month-old 5xFAD;Cx3cr1-/- mice express a 'degenerative' phenotype characterized by increased levels of Ccl2, Ccl5, Il-1β, Pten and Cybb along with reduced Tnf, Il-6 and Tgfβ1 mRNA.
Conclusions: Cx3cr1 deficiency impairs microglial uptake and degradation of fibrillar Aβ, thereby triggering increased accumulation of neurotoxic Aβ species. Furthermore, loss of Cx3cr1 results in microglial dysfunction typified by dampened TGFβ-signaling, increased oxidative stress responses and dysregulated pro-inflammatory activation. Our results indicate that Aβ-driven microglial dysfunction in Cx3cr1-/- mice aggravates tau hyperphosphorylation, neurodegeneration, synaptic dysregulation and impairs working memory.
Keywords: Amyloid; CX3CR1; Microglia; Neurodegeneration; Tau.
© 2022. The Author(s).
Conflict of interest statement
The authors have no competing interests to declare.
Figures
Similar articles
-
Heterozygous CX3CR1 Deficiency in Microglia Restores Neuronal β-Amyloid Clearance Pathways and Slows Progression of Alzheimer's Like-Disease in PS1-APP Mice.Front Immunol. 2019 Dec 2;10:2780. doi: 10.3389/fimmu.2019.02780. eCollection 2019. Front Immunol. 2019. PMID: 31849963 Free PMC article.
-
Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?Curr Alzheimer Res. 2016;13(4):403-12. doi: 10.2174/1567205013666151116125714. Curr Alzheimer Res. 2016. PMID: 26567742 Review.
-
CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models.Am J Pathol. 2010 Nov;177(5):2549-62. doi: 10.2353/ajpath.2010.100265. Epub 2010 Sep 23. Am J Pathol. 2010. PMID: 20864679 Free PMC article.
-
Poloxamer-188 Exacerbates Brain Amyloidosis, Presynaptic Dystrophies, and Pathogenic Microglial Activation in 5XFAD Mice.Curr Alzheimer Res. 2022;19(4):317-329. doi: 10.2174/1567205019666220509143823. Curr Alzheimer Res. 2022. PMID: 35579170 Free PMC article.
-
CX3CL1 Pathway as a Molecular Target for Treatment Strategies in Alzheimer's Disease.Int J Mol Sci. 2023 May 4;24(9):8230. doi: 10.3390/ijms24098230. Int J Mol Sci. 2023. PMID: 37175935 Free PMC article. Review.
Cited by
-
Noradrenergic signaling controls Alzheimer's disease pathology via activation of microglial β2 adrenergic receptors.Res Sq [Preprint]. 2024 Feb 26:rs.3.rs-3976896. doi: 10.21203/rs.3.rs-3976896/v1. Res Sq. 2024. PMID: 38464247 Free PMC article. Preprint.
-
Single-Cell RNA-seq reveals transcriptomic modulation of Alzheimer's disease by activated protein C.Aging (Albany NY). 2024 Feb 21;16(4):3137-3159. doi: 10.18632/aging.205624. Epub 2024 Feb 21. Aging (Albany NY). 2024. PMID: 38385967 Free PMC article.
-
Selection of suitable reference genes for gene expression studies in HMC3 cell line by quantitative real-time RT-PCR.Sci Rep. 2024 Jan 29;14(1):2431. doi: 10.1038/s41598-024-52415-7. Sci Rep. 2024. PMID: 38287074 Free PMC article.
-
Noradrenergic signaling controls Alzheimer's disease pathology via activation of microglial β2 adrenergic receptors.bioRxiv [Preprint]. 2023 Dec 4:2023.12.01.569564. doi: 10.1101/2023.12.01.569564. bioRxiv. 2023. PMID: 38106167 Free PMC article. Preprint.
-
The role of Nurr1-miR-30e-5p-NLRP3 axis in inflammation-mediated neurodegeneration: insights from mouse models and patients' studies in Parkinson's disease.J Neuroinflammation. 2023 Nov 22;20(1):274. doi: 10.1186/s12974-023-02956-x. J Neuroinflammation. 2023. PMID: 37990334 Free PMC article.
References
-
- Xu J, Zhang P, Huang Y, Zhou Y, Hou Y, Bekris LM, et al. Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer’s disease. Genome Res. 2021;31(10):1900-12. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
